Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Conditions: Breast Cancer, Familial Male; Radiotherapy; Complications; Chemotherapeutic Toxicity; Immune Checkpoint Inhibitor; CDK4/6 Inhibitor; Trastuzumab; Pertuzumab; PARP Inhibitor Interventions: Radiation: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients) Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Breast Cancer | Cancer | Cancer & Oncology | China Health | Herceptin | Hospitals | Research | Toxicology